1. Home
  2. CAN vs NNNN Comparison

CAN vs NNNN Comparison

Compare CAN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.17

Market Cap

427.9M

Sector

Technology

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$11.50

Market Cap

434.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
NNNN
Founded
2013
2021
Country
Singapore
Germany
Employees
N/A
27
Industry
Semiconductors
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
427.9M
434.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CAN
NNNN
Price
$0.17
$11.50
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$3.21
N/A
AVG Volume (30 Days)
10.7M
33.7K
Earning Date
05-19-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$63.64
N/A
P/E Ratio
N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$8.30
52 Week High
$2.22
$54.90

Technical Indicators

Market Signals
Indicator
CAN
NNNN
Relative Strength Index (RSI) 25.12 47.11
Support Level N/A $10.50
Resistance Level $0.56 $29.98
Average True Range (ATR) 0.02 1.48
MACD -0.01 0.63
Stochastic Oscillator 3.50 65.45

Price Performance

Historical Comparison
CAN
NNNN

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: